JACC Scientific Statement Addresses Management of HFpEF

April 19, 2023—The American College of Cardiology (ACC) announced the publication online of the “2023 ACC Expert Consensus Decision Pathway (ECDP) on the Management of Heart Failure (HF) with Preserved Ejection Fraction (HFpEF)” by Barry A. Bolaug, MD, et al in Journal of the American College of Cardiology (JACC).

Considering favorable clinical trial results assessing newer therapies, the ECDP writing committee addresses the differences in diagnostic criteria based on gender, and details practical treatment strategies of HFpEF.

According to ACC, the JACC Scientific Statement emphasizes the importance of a multidisciplinary care team approach to provide the full scope of care for patients because HF often comes with multiple overlapping comorbidities, including hypertension, diabetes, obesity, and sleep apnea.

The document lays out a structure for clinical decision-making, management of comorbidities, implementation of the latest guideline-directed medical therapy (both pharmacological and nonpharmacological), and equitable delivery of care.

In the JACC Scientific Statement, which was developed in a complementary fashion, the JACC Editorial Board and ACC Heart Failure and Transplant Section provide an in-depth analysis of the current epidemiology, pathophysiology, diagnosis, and treatment of HFpEF. The Scientific Statement also addresses knowledge gaps in care and future therapeutic strategies, advised ACC.

ACC noted that this document builds upon the recommendations from the “2022 American Heart Association/American College of Cardiology/Heart Failure Society of America Guideline for the Management of Heart Failure” by Paul A. Heidenreich, MD, et al (JACC; 2022;79:e263–e421).